The above evidence suggested that silencing ANRIL could promote ovarian cancer cell apoptosis, increase cisplatin-induced cell apoptosis and improve cisplatin-sensitivity by binding with PRC2 complexes to inhibit HMGA2. This evidence concerns the gene CDKN2B-AS1 and ovarian carcinoma.